GE HEALTHCARE TECHNOLOGIES INC.
In the published model solve dated 2026-Q2, anchored at $71.72, GE HEALTHCARE TECHNOLOGIES INC. (GEHC) is priced for +8.7% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 26, 2026 from SEC EDGAR filings.
• The profit does not sit where the revenue sits: Pharmaceutical Diagnostics, the injectable agents that make a scan readable, earned FY2025 segment profit of $872 million on $2,900 million of sales, almost matching the $891 million the Imaging equipment business earned on $9,245 million. • Trade policy is the largest single swing on earnings, and the FY2025 annual report puts the damage plainly: tariffs ⟦materially impacted our Operating income by approximately $245 million and cash flows by ap
Is GEHC overvalued? See what's priced in →
1,229 institutional managers reported holding GEHC in 13F filings for the quarter ended 2026-03-31. Together they hold about 83% of the company; the top 10 hold 48%. 102 opened new positions that quarter. Held by Vanguard Group, BlackRock, Dodge & Cox, among others. On the short side, 15.6M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (3.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
GEHC's share count is about flat over the past five years ($300.00M of repurchases, offset by issuance). It pays a dividend, and has paid one every year in our records (3 and counting), raised 2 years straight; the current rate is $0.14 a share annually. Cash returned over the past three years: $162.00M in dividends and $300.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at GEHC over the trailing three years: 2024: 1 buy totaling $101k; 2026: 1 buy totaling $642k. 22 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
GEHC's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-26 | -4.0% | -11.8% |
| 2023-11-01 | +8.1% | +11.5% |
| 2024-02-07 | +11.5% | +4.3% |
| 2024-05-01 | -12.0% | -1.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
GEHC's latest 8-K filings: 2026-08-18 (items 5.02, 9.01); 2026-07-29 (items 7.01, 9.01); 2026-07-29 (items 2.02, 9.01); 2026-07-23 (items 2.02, 5.02, 9.01); 2026-05-11 (items 5.07, 8.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 26, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.